Diagnostic and Prognostic Value of Adrenomedullin in Acute Ischemic and Hemorrhagic Strokes: A Systematic Review and Meta-Analysis.

Hamed Zarei, Mohammadhossein Vazirizadeh-Mahabadi, Narges Saadatipour, Maryam Pazhooha, Mostafa Hosseini, Mahmoud Yousefifard

Abstract readReview

PubMed Full text at PMC

In one paragraph

Review in Innovations in clinical neuroscience. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hamed Zarei *Drs. Zarei, Vazirizadeh-Mahabadi, Saadatipour, Pazhooha, and Yousefifard are with Physiology Research Center, Iran University of Medical Sciences, Tehran, Iran.

Mohammadhossein Vazirizadeh-Mahabadi *Drs. Zarei, Vazirizadeh-Mahabadi, Saadatipour, Pazhooha, and Yousefifard are with Physiology Research Center, Iran University of Medical Sciences, Tehran, Iran.

Narges SaadatipourDrs. Zarei, Vazirizadeh-Mahabadi, Saadatipour, Pazhooha, and Yousefifard are with Physiology Research Center, Iran University of Medical Sciences, Tehran, Iran.

Maryam PazhoohaDrs. Zarei, Vazirizadeh-Mahabadi, Saadatipour, Pazhooha, and Yousefifard are with Physiology Research Center, Iran University of Medical Sciences, Tehran, Iran.

Mostafa HosseiniDr. Hosseini is with Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.

Mahmoud YousefifardDrs. Zarei, Vazirizadeh-Mahabadi, Saadatipour, Pazhooha, and Yousefifard are with Physiology Research Center, Iran University of Medical Sciences, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEarly detection and outcome prediction of stroke are crucial for enhancing poststroke care. We explored the diagnostic and prognostic potential of bioactive adrenomedullin (bio-ADM) in stroke through a systematic review and meta-analysis.

methodsMedline, Embase, Scopus, and Web of Science were searched for studies measuring bio-ADM in patients with stroke. Diagnostic outcomes were confirmed via imaging, while prognostic outcomes included mortality and modified Rankin Scale (mRS). For meta-analysis, standardized mean differences (SMDs), pooled odds ratios (ORs), and sensitivity/specificity were synthesized.

resultsTen articles were included. Bio-ADM levels were significantly higher in patients with stroke compared to nonstroke control groups (SMD: 1.47; 95% confidence interval [CI]: 0.98-1.97). Subgroup analyses of acute ischemic stroke (SMD: 1.22; 95% CI: 0.34-2.11) and acute hemorrhagic stroke (SMD: 1.67; 95% CI: 1.07-2.26) demonstrated similar findings. Bio-ADM levels within the first 24 hours of a stroke were significantly higher in patients who died compared to those who survived (SMD: 1.35; 95% CI: 1.08-1.61). Pooled data analysis from multivariate models demonstrated no independent association between increased bio-ADM levels within the first 24 hours of admission and mortality (pooled adjusted OR: 1.11; 95% CI: 0.97-1.27;

conclusionBio-ADM is significantly elevated in both hemorrhagic and ischemic strokes and associated with mortality and poor outcomes, though it is not independently predictive of death.

Indexed as

Adrenomedullinbio-ADMbrain infarctioncerebrovascular disordersearly diagnosishemorrhagic strokeischemic strokepeptide hormonesprognosisstroke

Identifiers

PMID42027359

PMCPMC13101903

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.